Heparin identification test and purity test for OSCS in heparin sodium and heparin calcium by weak anion-exchange high-performance liquid chromatography

Biologicals

Volumn 38, Issue 5, 2010, Pages 539-543

  Hashii, Noritaka ^a   Kawasaki, Nana ^a   Itoh, Satsuki ^a   Qin, Yan ^a   Fujita, Naho ^b   Hattori, Toshiaki ^b   Miyata, Kazuyoshi ^c   Bando, Aya ^c   Sekimoto, Yuko ^c   Hama, Takeshi ^d   Kashimura, Masaki ^d   Tatsumi, Masashi ^e   Mabuchi, Kazunori ^e   Namekawa, Hiroshi ^e   Sakai, Toru ^f   Hirose, Mio ^g   Dobashi, Sei ^g   Shimahashi, Hirotoshi ^h   Koyama, Sadatoshi ⁱ   Herr, Susanne Odgaard ^j   Kawai, Kenzo ^k   Yoden, Hikaru ^k   Yamaguchi, Teruhide ^a   more..

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b Ajinomoto Co Ltd   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^d Tokyo Opera City Tower 3 20 2 ^*  (Japan)

^e SAWAI PHARMACEUTICAL CO LTD   (Japan)

^f Taiyo Pharmaceutical Industry Co Ltd   (Japan)

^g TERUMO CORPORATION   (Japan)

^h Nippon Zoki Pharmaceutical Co   (Japan)

ⁱ MOCHIDA PHARMACEUTICAL CO   (Japan)

^j LEO PHARMA A S   (Denmark)

^k Fuso Pharmaceutical Industries Ltd   (Japan)

more..

Author keywords

Dermatan sulfate; Heparin; Oversulfated chondroitin sulfate; WAX HPLC

Indexed keywords

CHONDROITIN SULFATE; HEPARIN; HEPARIN CALCIUM; OVERSULFATED CHONDROITIN SULFATE; UNCLASSIFIED DRUG;

ACCURACY; ANALYTIC METHOD; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CONTROLLED STUDY; DRUG CONTAMINATION; DRUG DETERMINATION; DRUG PURITY; DRUG SAFETY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUALITY CONTROL; REPRODUCIBILITY; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY;

ANION EXCHANGE RESINS; CHONDROITIN SULFATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; ELECTROPHORESIS, CAPILLARY; HEPARIN;

EID: 77956231126     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2010.04.002     Document Type: Article

References (15)

1. Capila I., Linhardt R.J. Heparin-protein interactions. Angew Chem Int Ed Engl 2002, 41(3):391-412.
2. Lindahl U. 'Heparin'-from anticoagulant drug into the new biology. Glycoconj J 2000, 17(7-9):597-605.
3. Casu B., Lindahl U. Structure and biological interactions of heparin and heparan sulfate. Adv Carbohydr Chem Biochem 2001, 57:159-206.
4. Rabenstein D.L. Heparin and heparan sulfate: structure and function. Nat Prod Rep 2002, 19(3):312-331.
5. Beyer T., Diehl B., Randel G., Humpfer E., Schafer H., Spraul M., et al. Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy. J Pharm Biomed Anal 2008, 48(1):13-19.
6. Maruyama T., Toida T., Imanari T., Yu G., Linhardt R.J. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr Res 1998, 306(1-2):35-43.
7. Guerrini M., Beccati D., Shriver Z., Naggi A., Viswanathan K., Bisio A., et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008, 26(6):669-675.
8. Kishimoto T.K., Viswanathan K., Ganguly T., Elankumaran S., Smith S., Pelzer K., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008, 358(23):2457-2467.
9. Heparin sodium revision bulletin. United States Pharmacopeia/National Formulary, The United States Pharmacopeial Convention; 2008.
10. Monograph heparin sodium 2009, European Pharmacopeia Supplement 6.4, Council of Europe.
11. Monograph heparin sodium 2009, Japanease Pharmacopoeia XV Supplement 2, Ministry of Health, Labour and Welfare.
12. Kakoi N., Kinoshita M., Kawasaki N., Yamaguchi T., Hayakawa T., Kakehi K. Capillary electrophoresis analysis of contaminants in heparin sodium for the Japanese pharmacopoeia purity test. Yakugaku Zasshi 2009, 129(10):1255-1264.
13. Trehy M.L., Reepmeyer J.C., Kolinski R.E., Westenberger B.J., Buhse L.F. Analysis of heparin sodium by SAX/HPLC for contaminants and impurities. J Pharm Biomed Anal 2009, 49(3):670-673.
14. Céline Houiste. Proposition of a new method to assess glycosaminoglycans contamination. EDQM; 2008. p. 45-52. [accessed 05.03.10]. http://www.edqm.eu/medias/fichiers/Session_1_Contamination_of_heparin_Part_2.pdf.
15. Pascal Anger. Utility of anion exchange HPLC coupled with depolymerization to monitor new contaminants. USP Washington; 2009. p. 1-8. [accessed 05.03.10]. http://www.usp.org/pdf/EN/meetings/workshops/heparin2009Ange2.pdf.